Association of hormone therapy and outcomes in COVID-19.

IF 3 3区医学 Q1 OBSTETRICS & GYNECOLOGY

Menopause: The Journal of The North American Menopause Society Pub Date : 2025-08-05 DOI:10.1097/GME.0000000000002598

Carol L Kuhle, Dietlind L Wahner-Roedler, Karen M Fischer, Jennifer St Sauver, Darrell R Schroeder, Ekta Kapoor, Stephanie S Faubion, Samantha Mannion, Hannah C Nordhues, Ivana T Croghan

{"title":"Association of hormone therapy and outcomes in COVID-19.","authors":"Carol L Kuhle, Dietlind L Wahner-Roedler, Karen M Fischer, Jennifer St Sauver, Darrell R Schroeder, Ekta Kapoor, Stephanie S Faubion, Samantha Mannion, Hannah C Nordhues, Ivana T Croghan","doi":"10.1097/GME.0000000000002598","DOIUrl":null,"url":null,"abstract":"Objectives: To investigate the association between hormone therapy use and severe outcomes due to COVID-19 in perimenopausal and postmenopausal women.Methods: Using the Rochester Epidemiology Project, we retrospectively searched for the records of women aged 40-65 years who had a documented case of COVID-19 between March 12 and September 29, 2020. We further identified those who were perimenopausal or postmenopausal. The rates of emergency department visits, hospitalizations, and deaths were compared by hormone therapy use. Logistic regression models were used to assess the odds of the combined outcome based on hormone therapy use.Results: Among the 689 patients included in this study, the median age was 56 years, and 77.5% were White. Compared with patients currently using hormone therapy, those with past/never use of hormone therapy were significantly older, had more risk factors for severe COVID-19, and had a higher incidence of diabetes. A total of 102 emergency department visits/hospitalizations/deaths occurred among both groups. Participants with current hormone therapy use had similar rates and risk of emergency department/hospitalization/death outcomes as those without hormone therapy, even after adjusting for age and severe COVID-19 risk factors.Conclusions: Severe COVID-19 outcomes were not significantly different between women with current versus past/never use of hormone therapy. Our study adds to the data suggesting no harm with hormone therapy use in women with severe symptoms of COVID-19.","PeriodicalId":18435,"journal":{"name":"Menopause: The Journal of The North American Menopause Society","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12500175/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Menopause: The Journal of The North American Menopause Society","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/GME.0000000000002598","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To investigate the association between hormone therapy use and severe outcomes due to COVID-19 in perimenopausal and postmenopausal women.

Methods: Using the Rochester Epidemiology Project, we retrospectively searched for the records of women aged 40-65 years who had a documented case of COVID-19 between March 12 and September 29, 2020. We further identified those who were perimenopausal or postmenopausal. The rates of emergency department visits, hospitalizations, and deaths were compared by hormone therapy use. Logistic regression models were used to assess the odds of the combined outcome based on hormone therapy use.

Results: Among the 689 patients included in this study, the median age was 56 years, and 77.5% were White. Compared with patients currently using hormone therapy, those with past/never use of hormone therapy were significantly older, had more risk factors for severe COVID-19, and had a higher incidence of diabetes. A total of 102 emergency department visits/hospitalizations/deaths occurred among both groups. Participants with current hormone therapy use had similar rates and risk of emergency department/hospitalization/death outcomes as those without hormone therapy, even after adjusting for age and severe COVID-19 risk factors.

Conclusions: Severe COVID-19 outcomes were not significantly different between women with current versus past/never use of hormone therapy. Our study adds to the data suggesting no harm with hormone therapy use in women with severe symptoms of COVID-19.

查看原文本刊更多论文

激素治疗与COVID-19预后的关系

目的：探讨围绝经期和绝经后妇女使用激素治疗与COVID-19严重结局之间的关系。方法：利用罗切斯特流行病学项目，回顾性检索2020年3月12日至9月29日期间有COVID-19病例记录的40-65岁女性的记录。我们进一步确定了围绝经期或绝经后的妇女。通过激素治疗的使用比较急诊科就诊率、住院率和死亡率。使用逻辑回归模型评估基于激素治疗使用的综合结果的几率。结果：本研究纳入689例患者，中位年龄56岁，白人占77.5%。与目前正在使用激素治疗的患者相比，过去或从未使用激素治疗的患者明显年龄更大，患严重COVID-19的危险因素更多，糖尿病发病率更高。两组共发生102例急诊科就诊/住院/死亡。即使在调整了年龄和严重的COVID-19风险因素后，目前使用激素治疗的参与者与未使用激素治疗的参与者的急诊科/住院/死亡结果的发生率和风险相似。结论：目前与过去/从未使用激素治疗的女性之间的严重COVID-19结局无显著差异。我们的研究补充了一些数据，表明在患有COVID-19严重症状的女性中使用激素疗法没有危害。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Menopause: The Journal of The North American Menopause Society 医学-妇产科学

CiteScore

5.40

自引率

7.40%

发文量

330

审稿时长

3-8 weeks

期刊介绍： Menopause, published monthly, provides a forum for new research, applied basic science, and clinical guidelines on all aspects of menopause. The scope and usefulness of the journal extend beyond gynecology, encompassing many varied biomedical areas, including internal medicine, family practice, medical subspecialties such as cardiology and geriatrics, epidemiology, pathology, sociology, psychology, anthropology, and pharmacology. This forum is essential to help integrate these areas, highlight needs for future research, and enhance health care.